ReviewInfection and drug resistance2016
Review in Infection and drug resistance, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 70 citations in OpenAlex.
- Pathogen Enzyme-Mediated Alkoxyamine Homolysis as a Killing Mechanism ofJournal of fungi (Basel, Switzerland) · 2025Article
- Highly Effective Modulator Therapy: Implications for the Microbial Landscape in Cystic Fibrosis.International journal of molecular sciences · 2024Review
- Elexacaftor/Tezacaftor/Ivacaftor Markedly ReducesAmerican journal of respiratory and critical care medicine · 2024Article
- Cystic fibrosis.Nature reviews. Disease primers · 2024Review
- Insights intoJournal of fungi (Basel, Switzerland) · 2024Article
- Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study.Scientific reports · 2023Article
- Pathogenicity and virulence ofVirulence · 2023Review
- Protective role of CFTR during fungal infection of cystic fibrosis bronchial epithelial cells withFrontiers in cellular and infection microbiology · 2023Article
- Exposure to theMicrobiology (Reading, England) · 2022Article
- Suppression ofFrontiers in microbiology · 2022Article
- Review
- Article
- Small Molecule CCR4 Antagonists Protect Mice fromBiomolecules · 2021Article
- Bacterial Interactions withMicroorganisms · 2021Review
- Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation.Journal of fungi (Basel, Switzerland) · 2020Review
- Parasexual recombination enablesERJ open research · 2020Article
- Azole-ResistantFrontiers in microbiology · 2020Article
- Modulated Response ofFrontiers in cellular and infection microbiology · 2020Article
- Salivary mycobiome dysbiosis and its potential impact on bacteriome shifts and host immunity in oral lichen planus.International journal of oral science · 2019Article
- Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.The Journal of antimicrobial chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.